Cardiotoxic safety communications after FDA approval of novel cancer therapies.
Bonsu J, Kola-Kehinde O, Kim L, Ruz P, Lustberg M, Brammer J, Addison D. Cardiotoxic safety communications after FDA approval of novel cancer therapies. Journal Of Clinical Oncology 2021, 39: e18629-e18629. DOI: 10.1200/jco.2021.39.15_suppl.e18629.Peer-Reviewed Original ResearchBlack box warningNovel anticancer therapiesHeart failureNovel cancer therapiesThromboembolic diseaseBox warningCancer therapyCardiovascular disease eventsAnticancer therapyMultivariable logistic regressionSudden cardiac deathApproval statusNew safety informationPriority review statusUncontrolled hypertensionCVD eventsCardiac deathCoronary diseaseCVD deathDrug withdrawalElectrocardiographic changesMyocardial infarctionDrug classesLabel warningsMultivariable modelDissemination of cancer survivorship care plans: who is being left out?
Timsina LR, Zarzaur B, Haggstrom DA, Jenkins PC, Lustberg M, Obeng-Gyasi S. Dissemination of cancer survivorship care plans: who is being left out? Supportive Care In Cancer 2021, 29: 4295-4302. PMID: 33415363, DOI: 10.1007/s00520-020-05915-x.Peer-Reviewed Original ResearchConceptsSurvivorship care plansCancer survivorsCare plansComprehensive survivorship care planCancer survivorship care plansLow educational achievementMultivariable logistic regressionSelf-reported receiptQuality of careAssociation of SDOHYounger patientsSurgeons CommissionCancer patientsPrimary careAmerican CollegeAdult populationSocial determinantsLogistic regressionPatientsSurvivorsLower likelihoodMarital statusCareFuture studiesReceipt